Bio-Techne Corp. - TECH STOCK NEWS

Bio-Techne Corporation (NASDAQ:TECH) announced the launch of the AmplideX^® PCR/CE CFTR Kit, designed to detect pathogenic variants in the CFTR gene, which is associated with cystic fibrosis. This new kit offers broader variant coverage for diverse populations, detecting approximately 93% of known pathogenic variants in the U.S. The assay delivers results in under five hours and includes push-button data analysis software. The launch underscores Bio-Techne's commitment to enhancing diagnostic accuracy across all ancestries.

Bio-Techne Corporation (NASDAQ: TECH) announced that its Executive Vice President and CFO, Jim Hippel, will present at the Credit Suisse 30th Annual Healthcare Conference on November 9, 2021, at 11:20 a.m. EST. The presentation will be available via a live webcast on Bio-Techne's Investor Relations website. The company specializes in high-quality purified proteins, reagents, and diagnostic products, generating approximately $931 million in net sales in fiscal 2021. Bio-Techne employs around 2,700 staff globally, focusing on advancing biological research and molecular diagnostics.

Bio-Techne Corporation (NASDAQ: TECH) announced the commercial launch of GMP-grade proteins from its new St. Paul, MN facility, focusing on large-scale production for cell and gene therapy workflows. This investment of $50 million enhances its capacity to meet the increasing demand driven by over 1300 ongoing clinical trials in cell therapy, marking a 43% increase from the previous year. The facility's state-of-the-art technology and scalability aim to ensure lot-to-lot consistency and patient safety in GMP manufacturing.

Bio-Techne Corporation (NASDAQ:TECH) reported first quarter FY2022 financial results, highlighting a 26% increase in net sales to $257.7 million, driven by 21% organic revenue growth. GAAP EPS rose to $1.69 from $0.83 last year, while adjusted EPS was $1.83, up from $1.43. The Protein Sciences segment experienced 28% growth, with organic growth of 26%. Diagnostic and Genomics segment sales grew 22%. Strong commercial execution was noted across all regions, with China seeing growth over 50%. The company remains optimistic about its Cell and Gene Therapy initiatives.

Bio-Techne Corporation (NASDAQ: TECH) announced a quarterly dividend of $0.32 per share for Q3 2021, payable on November 26, 2021. Shareholders of record as of November 12, 2021 will receive this dividend. With approximately $931 million in net sales in fiscal 2021, Bio-Techne continues to support research and clinical diagnostics as a leading provider of innovative tools and bioactive reagents globally.

Bio-Techne Corporation (NASDAQ:TECH) announced the publication of significant clinical research by Exosome Diagnostics in Prostate Cancer and Prostatic Diseases. The study reveals that the ExoDx Prostate Intelliscore test can effectively distinguish between high-grade and low-grade prostate cancers, potentially reducing unnecessary biopsies by 23%. With an impressive negative predictive value of 90%, this test aids in making informed biopsy decisions, aligning with updated NCCN guidelines. Dr. Johan Skog emphasized its importance in reducing overdiagnosis risks, empowering patients and physicians alike.

Bio-Techne Corporation (NASDAQ: TECH) announced a conference call and webcast on November 2, 2021, at 8:00 a.m. CDT to discuss its first quarter 2022 financial results. Investors can access the call via dial-in or webcast. A recorded replay will be available from 11:00 a.m. CDT on the same day until 11:00 p.m. CST on December 2, 2021. Bio-Techne, known for developing high-quality reagents and diagnostic products, generated approximately $931 million in net sales in fiscal 2021 and employs around 2,700 staff globally.

Bio-Techne (NASDAQ: TECH) has launched ExCellerate™ iPSC Expansion Medium, designed for the expansion and maintenance of induced pluripotent stem cells (iPSCs). This new medium supports research and clinical applications in regenerative medicine, as it is animal component-free and includes essential growth factors for iPSC maintenance. It provides a consistent cell culture environment, allowing for reliable performance in generating homogeneous iPSCs. The launch signifies Bio-Techne's commitment to advancing innovative solutions for researchers in cell and gene therapies.